Name: AcLysValCit-PABC-DMAE-SW-163D
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Canonical SMILES

CC1CC12C(=O)OCC(C(=O)NC(C(=O)N(C3C(SCC(C(=O)N2C)N(C(=O)C(NC(=O)C(COC(=O)C4(CC4C)N(C3=O)C)NC(=O)C5=NC6=CC=CC=C6C=C5O)C)C)SC)C)C)NC(=O)C7=NC8=CC=CC=C8C=C7OC(=O)N(C)CCN(C)C(=O)OCC9=CC=C(C=C9)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C

InChI

InChI=1S/C85H113N19O22S2/c1-44(2)63(98-68(108)56(91-49(7)105)26-19-20-32-86)71(111)95-57(27-21-33-88-81(87)120)67(107)92-53-30-28-50(29-31-53)40-125-82(121)99(8)34-35-100(9)83(122)126-62-37-52-23-16-18-25-55(52)94-65(62)73(113)97-59-42-123-79(118)84(38-45(84)3)103(12)76(116)60-43-128-78(127-14)66(102(11)75(115)48(6)90-70(59)110)77(117)104(13)85(39-46(85)4)80(119)124-41-58(69(109)89-47(5)74(114)101(60)10)96-72(112)64-61(106)36-51-22-15-17-24-54(51)93-64/h15-18,22-25,28-31,36-37,44-48,56-60,63,66,78,106H,19-21,26-27,32-35,38-43,86H2,1-14H3,(H,89,109)(H,90,110)(H,91,105)(H,92,107)(H,95,111)(H,96,112)(H,97,113)(H,98,108)(H3,87,88,120)/t45-,46-,47-,48-,56+,57-,58+,59+,60-,63-,66+,78-,84-,85-/m0/s1

Solubility

10 mm in DMSO

Appearance

Solid

Shelf Life

0-4°C for short term (days to weeks), or -20°C for long term (months).

Shipping

-20°C (International: -20°C)

Storage

Store at -5°C,keep in dry and avoid sunlight.

Form

Solid

AcLysValCit-PABC-DMAE-SW-163D is a complex compound primarily used in targeted drug delivery systems. Here are some key applications of AcLysValCit-PABC-DMAE-SW-163D:

Cancer Therapy: AcLysValCit-PABC-DMAE-SW-163D can be conjugated with cytotoxic drugs to form antibody-drug conjugates (ADCs) that specifically target cancer cells. This targeted approach minimizes damage to healthy cells and reduces side effects associated with traditional chemotherapy. The compound acts as a linker, enabling the precise release of the therapeutic agent within the tumor microenvironment.

Immunotherapy: In immunotherapy, AcLysValCit-PABC-DMAE-SW-163D can be used to enhance the delivery and effectiveness of immune-modulating drugs. By attaching immunotherapeutic agents to this linker, the drug can be more accurately directed to immune cells or cancer cells. This helps in boosting the body's immune response against tumors and improving treatment outcomes.

Bioconjugation Research: AcLysValCit-PABC-DMAE-SW-163D serves as a versatile linker in bioconjugation studies, facilitating the development of new drug delivery systems. Researchers can use it to link a wide variety of therapeutic molecules to targeting moieties, such as antibodies or peptides. This broadens the range of diseases that can be targeted with precision medicine approaches.

Diagnostic Imaging: The compound can also be applied in diagnostic imaging, where it aids in the targeted delivery of imaging agents. By conjugating imaging molecules with AcLysValCit-PABC-DMAE-SW-163D, clinicians can achieve more precise localization of disease sites using advanced imaging techniques. This improves the accuracy of diagnostics and enables better monitoring of disease progression and treatment efficacy.